Acquisition
Video: Valeant buys rights to Visudyne Add to ...
Valeant Pharmaceuticals has purchased the rights to Visudyne, an eye drug, from Vancouver-based QLT Inc.
Watch More Video:
-
H&M posts sharp sales gains
European car sales hit 20-year low
Housing market poised for soft landing, says CREA
Consumer ka-ching for retailers
-
Busted: Dishonest B.C. realtor admits to altering sales documents
Valeant sticks to plan with $8.7-billion eye-care deal
Do we still need real estate agents?
Why this Toronto loft sold for under asking
-
Macy's rings up $6.39-billion sales
Retail sales unexpectedly rise
Briton jailed for bomb detector scam
Stressed consumers are paying more - but not getting more
-
McDonald's: Slow times for fast food
Long winter cools H&M sales
Daily Digit: U.S. retail sales slip again
Lukewarm retail sales blamed on weather chill
-
Car prices on the rise as auto industry picks up speed
B.C. makes history by eliminating HST
How long can S&P home-building stocks outpace index average?
After dead pig scandal, worries about safety of China's pork
<
>
| Security | Price | Change | |
|---|---|---|---|
| QLT-T QLT Inc. | 8.45 |
-0.12 -1.40% |
Add to watchlist |
| VRX-T Valeant Pharmaceuticals Intl. | 88.64 |
0.90 1.026% |
Add to watchlist |
